INDPIndaptus Therapeutics, Inc.
Earnings
When Indaptus Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
27 quarters. Mar 31, 2020 to Sep 30, 2026. mixed units.
Next results · Q4 2026Projected
10-K due Mar 10 – 24
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 5 filings.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 10 – 24
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$8.11M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- —
- —
- Net income
- -$1.05M
- N/M
- EPS
- -$0.01
- N/M
- Revenue
- —
- —
- Net income
- -$1.79M
- N/M
- EPS
- -$0.02
- N/M
- Revenue
- —
- —
- Net income
- -$2.54M
- N/M
- EPS
- -$0.23
- N/M
- Revenue
- —
- —
- Net income
- -$8.11M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 13, 2026 · after-hours | Nov 13, 2026 | 44 d | 10-Q | — | — | -$0.01 | — | |
| Q2 2026 | Jun 30, 2026 | Aug 13, 2026 · pre-market | Aug 13, 2026 | 44 d | 10-Q | — | — | -$0.02 | 4.6% | |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 · pre-market | May 15, 2026 | 45 d | 10-Q | — | — | -$0.23 | 9.9% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | — | Mar 17, 2026 | 76 d | 10-K | — | — | — | +5.1% | |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 · pre-market | Nov 12, 2025 | 43 d | 10-Q | — | — | -$2.98 | +6.3% | |
| Q2 2025 | Jun 30, 2025 | Aug 13, 2025 · pre-market | Aug 13, 2025 | 44 d | 10-Q | — | — | -$9.09 | 0.7% | |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 · pre-market | May 14, 2025 | 44 d | 10-Q | — | — | -$9.11 | +7.5% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 13, 2025 · pre-market | Mar 13, 2025 | 72 d | 10-K | — | — | — | 5.8% | |
| Q3 2024 | Sep 30, 2024 | Nov 12, 2024 · pre-market | Nov 12, 2024 | 43 d | 10-Q | — | — | -$9.04 | 1.7% | |
| Q2 2024 | Jun 30, 2024 | Aug 12, 2024 · pre-market | Aug 12, 2024 | 43 d | 10-Q | — | — | -$13.16 | 2.3% | |
| Q1 2024 | Mar 31, 2024 | May 8, 2024 · pre-market | May 8, 2024 | 38 d | 10-Q | — | — | -$0.45 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 13, 2024 · pre-market | Mar 13, 2024 | 73 d | 10-K | — | — | — | 4.8% | |
| Q3 2023 | Sep 30, 2023 | Nov 6, 2023 · after-hours | Nov 6, 2023 | 37 d | 10-Q | — | — | -$0.47 | 3.6% | |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 · pre-market | Aug 14, 2023 | 45 d | 10-Q | — | — | -$0.39 | — | |
| Q1 2023 | Mar 31, 2023 | May 11, 2023 · pre-market | May 11, 2023 | 41 d | 10-Q | — | — | -$0.51 | 7.1% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 17, 2023 · pre-market | Mar 17, 2023 | 76 d | 10-K | — | — | — | +3.2% | |
| Q3 2022 | Sep 30, 2022 | Nov 10, 2022 · after-hours | Nov 10, 2022 | 41 d | 10-Q | — | — | -$0.42 | — | |
| Q2 2022 | Jun 30, 2022 | Aug 8, 2022 · pre-market | Aug 8, 2022 | 39 d | 10-Q | — | — | -$0.46 | +0.9% | |
| Q1 2022 | Mar 31, 2022 | May 12, 2022 · pre-market | May 12, 2022 | 42 d | 10-Q | — | — | — | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Mar 21, 2022 · pre-market | Mar 21, 2022 | 80 d | 10-K | — | — | — | 0.8% | |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 · pre-market | Nov 15, 2021 | 46 d | 10-Q | — | — | -$0.81 | 9.9% | |
| Q2 2021 | Jun 30, 2021 | — | Aug 16, 2021 | 47 d | 10-Q | — | — | -$5.53 | 2.1% | |
| Q1 2021 | Mar 31, 2021 | — | Jun 28, 2021 | 89 d | 10-Q | — | — | — | — | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | — | — | — | — | — | — | — | — | |
| Q3 2020 | Sep 30, 2020 | — | — | — | — | — | — | -$0.79 | — | |
| Q2 2020 | Jun 30, 2020 | — | — | — | — | — | — | -$3.66 | — | |
| Q1 2020 | Mar 31, 2020 | — | — | — | — | — | — | — | — | |
Earlier years, FY 2020 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Indaptus Therapeutics, Inc. · CIK 1857044 · Engraved from SEC EDGAR